News | November 15, 2023
Natco Pharma posts consolidated Q2F Y24 PAT of Rs. 369 Cr
Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023
Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023
Solara Active Pharma Sciences has reported total income of Rs. 426.42 crores during the period ended September 30, 2023
Yesafili, received marketing authorization approval from the European Commission for the European Union
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
he company posted total income during Q2 FY24 at Rs. 12.86 crore
European operations' revenue grew 58.4% to Rs 599.7 crore
General Medicine grows 5% and Vaccines 10% led by Shingrix
Subscribe To Our Newsletter & Stay Updated
